Tofacitinib in Acute Severe Ulcerative Colitis-A Real-World Tertiary Center Experience

Inflamm Bowel Dis. 2020 Oct 23;26(11):e147-e149. doi: 10.1093/ibd/izaa157.

Authors

Sailish Honap¹, Polychronis Pavlidis^{1

2}, Shuvra Ray¹, Esha Sharma¹, Simon Anderson¹, Jeremy D Sanderson^{1

3}, Joel Mawdsley¹, Mark A Samaan¹, Peter M Irving^{1

4}

Affiliations

¹ IBD Centre, Guy's and St Thomas' Hospitals NHS Foundation Trust, London,United Kingdom.
² Centre for Inflammation Biology and Cancer Immunology, King's College London , London, United Kingdom.
³ Division of Nutritional Sciences, King's College London, London,United Kingdom.
⁴ School of Immunology and Microbial Sciences, King's College London , London, United Kingdom.

PMID: 32566937
DOI: 10.1093/ibd/izaa157

No abstract available

Keywords: JAK inhibitor; tofacitinib; ulcerative colitis.

Publication types

Letter

MeSH terms

Acute Disease
Adult
Colitis, Ulcerative / drug therapy*
Colitis, Ulcerative / pathology
Female
Humans
Male
Middle Aged
Piperidines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Retrospective Studies
Severity of Illness Index
Tertiary Care Centers
Treatment Outcome
Young Adult

Substances

Piperidines
Protein Kinase Inhibitors
Pyrimidines
tofacitinib